$Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review$

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review

Introduction and objective Multiple myeloma (MM) is an incurable condition with variable clinical course. The study included a group of patients with especially poor-prognosis, individuals with relapsed/refractory multiple myeloma (RRMM) and specific cytogenetic disorders. Among the currently used t...

Full description

Bibliographic Details
Main Authors:	Aneta Szudy-Szczyrek, Sylwia Chocholska, Oliwia Bachanek-Mitura, Olga Czabak, Radosław Mlak, Michał Szczyrek, Justyna Muzyka-Kasietczuk, Marek Hus
Format:	Article
Language:	English
Published:	Institute of Rural Health 2021-06-01
Series:	Annals of Agricultural and Environmental Medicine
Subjects:	lenalidomide high risk ixazomib cytogenetic relapsed/refractory multiple myeloma
Online Access:	http://www.aaem.pl/Efficacy-of-ixazomib-lenalidomide-dexamethasone-in-high-molecular-risk-relapsed-refractory,137788,0,2.html

Similar Items

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024-04-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
by: Tran-Der Tan, et al.
Published: (2020-01-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
by: Shutan Li, et al.
Published: (2023-03-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
by: Hira Mian, et al.
Published: (2022-02-01)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
by: Andrew Spencer, et al.
Published: (2022-11-01)

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience
by: Mustafa Merter, et al.
Published: (2022-06-01)

Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective
by: Lineo Marie Matsela, et al.
Published: (2022-12-01)

Ixazomib-associated skin exfoliation
by: Yali Zhang, et al.
Published: (2022-04-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting
by: Winfried Alsdorf, et al.
Published: (2024-08-01)

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
by: Ying Shang, et al.
Published: (2023-12-01)

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
by: Wanlu Ma, et al.
Published: (2021-02-01)

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
by: Jingjing Ma, et al.
Published: (2022-07-01)

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
by: Robin Noel, et al.
Published: (2023-12-01)

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma
by: Aneta Szudy-Szczyrek, et al.
Published: (2022-02-01)

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialResearch in context
by: Ashwath Gurumurthi, et al.
Published: (2024-08-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01)

Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01)

Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions
by: Yunzhou Fan, et al.
Published: (2021-02-01)

Lenalidomide Combined with Interferon α-1b and Interleukin-2 in the Treatment of 21 Cases of Acute Myeloid Leukemia
by: Cheng Cheng, et al.
Published: (2021-08-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context
by: Kaz Groen, et al.
Published: (2023-09-01)

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2015-02-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

The TT Genotype of the <i>KIAA1524 rs2278911</i> Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma
by: Aneta Szudy-Szczyrek, et al.
Published: (2023-03-01)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
by: Richardson PG, et al.
Published: (2017-08-01)

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.
by: Nathan W Cummins, et al.
Published: (2021-12-01)

Therapy of Angiosarcoma with Thalidomide and Lenalidomide
by: M. Jules Mattes, et al.
Published: (2021-11-01)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
by: Satoko Oka, et al.
Published: (2021-06-01)